# Nemesis Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nemesis-bioscience

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.nemesisbio.com
- Total disclosed funding: $0.9M
- Latest round: Seed (May 7, 2017)
- Investors on record: 2

## About

Nemesis Bioscience Ltd. specializes in developing innovative biotechnologies aimed at tackling infectious diseases and antibiotic resistance. The company focuses on harnessing cutting-edge science to protect public health through advanced solutions.Nemesis Bioscience Ltd. was founded in 2014 in Cambridge, UK, focusing on biotechnological solutions to combat infectious diseases. The company has undergone strategic pivots to enhance its offerings but has not reported any changes in ownership or subsidiaries. The latest funding round occurred in May 2017, where Rainbow Seed Fund led a Seed round totaling GBP 0.7 million, with participation from Finance Wales and other individual investors. The firm's CEO and Founder information is currently unavailable.Nemesis Bioscience Ltd. offers a range of biotechnology products aimed at addressing infectious diseases and antibiotic resistance. Their primary offerings include advanced diagnostic tools and therapeutic solutions. The company caters to healthcare providers and research institutions, focusing on delivering innovative solutions that improve patient outcomes. Their geographical market extends globally, with a strong emphasis on regions requiring robust healthcare interventions, including Europe.The company's revenue is generated primarily through the sale of biotechnology products and services aimed at combating infectious diseases. Revenue is structured through direct sales and partnerships with healthcare institutions. The pricing model is designed to accommodate various customers, ensuring that both small clinics and larger healthcare systems can access their innovative solutions. By establishing partnerships and providing tailored products, the firm seeks to build lasting client relationships that contribute to a stable revenue stream.Nemesis Bioscience Ltd. plans to utilize the GBP 0.7 million raised in their most recent Seed funding round to enhance their research capabilities and accelerate the development of new products aimed at addressing urgent healthcare needs. The company is targeting expansion into the European and North American markets by 2025, focusing on collaborations with healthcare providers to introduce their innovative solutions. Upcoming product launches include advanced diagnostic tools scheduled for release in early 2024, aimed at improving detection and treatment of infectious diseases.

## Funding rounds

- Seed, May 7, 2017, $0.9M — Development Bank of Wales, Rainbow Seed Fund

## Investors

- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Seed
- Rainbow Seed Fund — Seed